Answers are grounded in this paper and cite their sources.
Into the fold: Prion diseases are neurodegenerative disorders characterized by the accumulation in the brain of a self-replicating, misfolded isoform (PrPSc) of the cellular prion protein (PrPC). No therapies are available for these pathologies. We capitalized on previously described cell-based assays to screen a library of small molecules, and identified 55, a compound capable of counteracting both prion replication and toxicity. Compound 55 may represent the starting point for the development of a completely new class of therapeutics for prion diseases.
No takes yet. Share an insight, caveat, or question.
Massignan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: